Bluejay Diagnostics, Inc. Stock

Equities

BJDX

US0956333019

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
0.625 USD +0.81% Intraday chart for Bluejay Diagnostics, Inc. +13.43% -48.77%
Sales 2024 * - Sales 2025 * 1.64M Capitalization 1.68M
Net income 2024 * -7M Net income 2025 * -8M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.03 x
P/E ratio 2024 *
-0.19 x
P/E ratio 2025 *
-0.19 x
Employees 10
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.08%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.81%
1 week+13.43%
Current month-22.15%
1 month-23.78%
3 months-25.93%
6 months-85.57%
Current year-48.77%
More quotes
1 week
0.47
Extreme 0.472
0.65
1 month
0.47
Extreme 0.4703
0.82
Current year
0.47
Extreme 0.4703
1.22
1 year
0.47
Extreme 0.4703
13.98
3 years
0.47
Extreme 0.4703
125.00
5 years
0.47
Extreme 0.4703
125.00
10 years
0.47
Extreme 0.4703
125.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 14-12-31
Founder 52 14-12-31
Chief Administrative Officer - -
Members of the board TitleAgeSince
Director/Board Member 77 21-04-30
Director/Board Member 77 16-12-31
Director/Board Member 59 21-11-14
More insiders
Date Price Change Volume
24-04-22 0.62 +12.73% 41,204
24-04-19 0.55 -0.60% 25,151
24-04-18 0.5533 +0.60% 28,754
24-04-17 0.55 -0.18% 16,366
24-04-16 0.551 -6.61% 57,135

Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT

More quotes
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
More about the company